Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“Four Key Developments in Oncology This Week
Four Phase III trials. Four different lessons.
- ATOMIC: DFS benefit → New FDA approval
- HER2CLIMB-05: PFS benefit → New FDA approval
- EPCORE DLBCL-2: Promising Phase III results
- FURVENT: High ORR, negative primary endpoint
A promising response is not the same as proven clinical benefit. What really changes oncology practice?”
You can also read: Who Shaped Oncology in the First Half of 2026: Breaking Down Approvals by Indications
